Soligenix Advances Oral Mucositis Treatment SGX942 with Combined Clinical Data Analysis
Soligenix is leveraging positive phase 2 and 3 clinical data to design a second pivotal trial for SGX942, addressing the critical unmet medical need for oral mucositis treatment in cancer patients.
Soligenix Inc. (NASDAQ: SNGX) is analyzing combined phase 2 and 3 clinical datasets to design a second pivotal phase 3 study for its novel therapeutic SGX942 (dusquetide), aimed at treating oral mucositis in cancer patients. This debilitating side effect of cancer therapy currently has no FDA-approved treatment, often necessitating hospitalization, opioid pain management, and feeding tube placement, which substantially lowers patients' quality of life.
The company's development of SGX942 addresses a critical unmet medical need, as effective treatment or prevention is essential for ensuring cancer therapies remain on schedule while helping patients maintain nutrition and comfort. Soligenix is also in the process of identifying potential partners to continue this development program, which represents a significant advancement in supportive care for cancer patients undergoing treatment.
For further information about the company's development programs, visit https://www.Soligenix.com. Additional news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
The advancement of SGX942 through clinical development demonstrates Soligenix's commitment to addressing serious complications of cancer treatment that significantly impact patient outcomes and quality of life. The company's progress in this area may lead to improved supportive care options for cancer patients worldwide.